These are top 10 stocks traded on the Robinhood UK platform in July
FREMONT, Calif. - Tivic Health Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company with a current market capitalization of $3.22 million, has announced a 1-for-17 reverse stock split of its common stock, scheduled to take effect on March 7, 2025. Trading at $0.34 per share, the stock has experienced significant volatility, falling 72.8% over the past year. This strategic move aims to comply with Nasdaq’s minimum bid price requirement, as part of the company’s Compliance Plan submitted to Nasdaq on February 18, 2025.InvestingPro analysis indicates the company maintains a strong liquidity position with a current ratio of 5.65, though recent market performance has been challenging. Subscribers can access 15 additional key insights about TIVC’s financial health and market position.
Approved by shareholders on January 31, 2025, the reverse stock split is designed to raise the per-share trading price of the company’s common stock on the Nasdaq Capital Market to satisfy the exchange’s listing standards. According to InvestingPro data, the company’s overall financial health score stands at 2.07, rated as ’FAIR,’ with particularly strong metrics in cash management. The company’s stock is expected to begin trading on a split-adjusted basis upon market opening on the effective date, retaining the ticker symbol TIVC.
The reverse stock split will consolidate every 17 shares of issued and outstanding common stock into one new share. This will proportionately adjust the conversion and exercise prices of the company’s preferred stock, outstanding warrants, equity awards, and options, along with the shares reserved under the amended and restated 2021 equity incentive plan.
No change will occur in the number of preferred stock shares issued and outstanding, the authorized shares of common or preferred stock under the company charter, or the par value of the stocks. Stockholders’ percentage ownership and voting power will remain essentially unchanged, except for adjustments due to the rounding of fractional shares into whole shares. No fractional shares will be issued; instead, stockholders will receive one whole share in lieu of any fractional shares.
Equiniti Trust Company is managing the exchange process for the reverse stock split. Shareholders using book-entry forms or with shares held through a bank, broker, or other nominee need not take any action. Registered stockholders will receive information from Equiniti regarding the changes to their stock ownership following the split.
Previously, in December 2024, Nasdaq had notified Tivic Health of its intent to delist the company’s stock due to non-compliance with listing requirements. While the company holds more cash than debt on its balance sheet, financial metrics reveal a challenging operating environment with an EBITDA of -$6.36 million in the last twelve months. The company appealed this decision and believes the reverse stock split will enable it to meet Nasdaq’s continued listing requirements.Get comprehensive insights into TIVC’s financial health and future prospects with InvestingPro, including detailed analysis of cash flow patterns and growth potential.
This restructuring effort follows Tivic Health’s ongoing development of bioelectronic devices and biopharmaceuticals, including an FDA-approved device for sinus pain relief and a late-stage candidate for acute radiation syndrome treatment.
The information regarding the reverse stock split and Tivic Health’s corporate activities is available on the SEC’s website and the company’s official site. This news is based on a press release statement from Tivic Health Systems, Inc.
In other recent news, Tivic Health Systems has filed a new patent application with the U.S. Patent Office for a personalized vagus nerve stimulation device, which could enhance the efficacy of its non-invasive therapies. The company is also facing potential delisting from the Nasdaq Stock Market due to non-compliance with the exchange’s minimum bid price requirement. Despite this challenge, Tivic Health has requested a hearing to address the delisting notice, temporarily halting any delisting actions. In a related move, shareholders have approved a reverse stock split proposal, allowing the Board of Directors to consolidate shares at a ratio between 1-for-2 and 1-for-30 to potentially increase the market price of its common stock. Additionally, Tivic Health issued a shareholder letter outlining its dedication to innovative healthcare solutions and maintaining transparency with investors. The company cautioned that forward-looking statements in the letter involve risks and uncertainties. These developments reflect Tivic Health’s ongoing efforts to navigate regulatory and market challenges while advancing its medical device innovations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.